On the availability of SMA treatment for adults in Romania 

The petitioner is a 27-year-old that suffers from spinal muscular atrophy (SMA), a rare and often fatal genetic disease that causes muscle weakness and progressive loss of movement. The petitioner points out that the only drug that could help in the treatment of her severe condition, which was granted orphan designation by the European Commission in 2012 and authorised in the EU as Spinraza in 2017, is made available in Romania solely to children under 18 years old. The petitioner considers that this amounts to discrimination based on age and seeks access to treatment.